BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 26894988)

  • 1. Codelivery of Doxorubicin and shAkt1 by Poly(ethylenimine)-Glycyrrhetinic Acid Nanoparticles To Induce Autophagy-Mediated Liver Cancer Combination Therapy.
    Wang FZ; Xing L; Tang ZH; Lu JJ; Cui PF; Qiao JB; Jiang L; Jiang HL; Zong L
    Mol Pharm; 2016 Apr; 13(4):1298-307. PubMed ID: 26894988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced delivery of doxorubicin to the liver through self-assembled nanoparticles formed via conjugation of glycyrrhetinic acid to the hydroxyl group of hyaluronic acid.
    Wang X; Gu X; Wang H; Yang J; Mao S
    Carbohydr Polym; 2018 Sep; 195():170-179. PubMed ID: 29804965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doxorubicin-loaded glycyrrhetinic acid modified recombinant human serum albumin nanoparticles for targeting liver tumor chemotherapy.
    Qi WW; Yu HY; Guo H; Lou J; Wang ZM; Liu P; Sapin-Minet A; Maincent P; Hong XC; Hu XM; Xiao YL
    Mol Pharm; 2015 Mar; 12(3):675-83. PubMed ID: 25584860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insight into the role of dual-ligand modification in low molecular weight heparin based nanocarrier for targeted delivery of doxorubicin.
    Du H; Liu M; Yu A; Ji J; Zhai G
    Int J Pharm; 2017 May; 523(1):427-438. PubMed ID: 28359815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycyrrhetinic acid-conjugated polymeric prodrug micelles co-delivered with doxorubicin as combination therapy treatment for liver cancer.
    Yang T; Lan Y; Cao M; Ma X; Cao A; Sun Y; Yang J; Li L; Liu Y
    Colloids Surf B Biointerfaces; 2019 Mar; 175():106-115. PubMed ID: 30529816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pulmonary Codelivery of Doxorubicin and siRNA by pH-Sensitive Nanoparticles for Therapy of Metastatic Lung Cancer.
    Xu C; Wang P; Zhang J; Tian H; Park K; Chen X
    Small; 2015 Sep; 11(34):4321-33. PubMed ID: 26136261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Doxorubicin-loaded glycyrrhetinic acid-modified alginate nanoparticles for liver tumor chemotherapy.
    Zhang C; Wang W; Liu T; Wu Y; Guo H; Wang P; Tian Q; Wang Y; Yuan Z
    Biomaterials; 2012 Mar; 33(7):2187-96. PubMed ID: 22169820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocellular carcinoma dually-targeted nanoparticles for reduction triggered intracellular delivery of doxorubicin.
    Mezghrani O; Tang Y; Ke X; Chen Y; Hu D; Tu J; Zhao L; Bourkaib N
    Int J Pharm; 2015 Jan; 478(2):553-68. PubMed ID: 25455765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of intracellular reduction-sensitive amphiphilic polyethyleneimine and poly(ε-caprolactone) graft copolymer for on-demand release of doxorubicin and p53 plasmid DNA.
    Davoodi P; Srinivasan MP; Wang CH
    Acta Biomater; 2016 Jul; 39():79-93. PubMed ID: 27154500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal of multidrug resistance in MCF-7/Adr cells by codelivery of doxorubicin and BCL2 siRNA using a folic acid-conjugated polyethylenimine hydroxypropyl-β-cyclodextrin nanocarrier.
    Li JM; Zhang W; Su H; Wang YY; Tan CP; Ji LN; Mao ZW
    Int J Nanomedicine; 2015; 10():3147-62. PubMed ID: 25960653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Self-assembly and liver targeting of sulfated chitosan nanoparticles functionalized with glycyrrhetinic acid.
    Tian Q; Wang XH; Wang W; Zhang CN; Wang P; Yuan Z
    Nanomedicine; 2012 Aug; 8(6):870-9. PubMed ID: 22100756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acid-sensitive polymeric vector targeting to hepatocarcinoma cells via glycyrrhetinic acid receptor-mediated endocytosis.
    Yan T; Cheng J; Liu Z; Cheng F; Wei X; Huang Y; He J
    Mater Sci Eng C Mater Biol Appl; 2018 Jun; 87():32-40. PubMed ID: 29549947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biocompatible cationic pullulan-g-desoxycholic acid-g-PEI micelles used to co-deliver drug and gene for cancer therapy.
    Chen L; Ji F; Bao Y; Xia J; Guo L; Wang J; Li Y
    Mater Sci Eng C Mater Biol Appl; 2017 Jan; 70(Pt 1):418-429. PubMed ID: 27770912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Vivo Antitumor Activity of Folate-Conjugated Cholic Acid-Polyethylenimine Micelles for the Codelivery of Doxorubicin and siRNA to Colorectal Adenocarcinomas.
    Amjad MW; Amin MC; Katas H; Butt AM; Kesharwani P; Iyer AK
    Mol Pharm; 2015 Dec; 12(12):4247-58. PubMed ID: 26567518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycyrrhetinic acid-modified chitosan/poly(ethylene glycol) nanoparticles for liver-targeted delivery.
    Tian Q; Zhang CN; Wang XH; Wang W; Huang W; Cha RT; Wang CH; Yuan Z; Liu M; Wan HY; Tang H
    Biomaterials; 2010 Jun; 31(17):4748-56. PubMed ID: 20303163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycyrrhizin Acid and Glycyrrhetinic Acid Modified Polyethyleneimine for Targeted DNA Delivery to Hepatocellular Carcinoma.
    Cao M; Gao Y; Zhan M; Qiu N; Piao Y; Zhou Z; Shen Y
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31614879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional alginate nanoparticles for efficient intracellular release of doxorubicin and hepatoma carcinoma cell targeting therapy.
    Guo H; Lai Q; Wang W; Wu Y; Zhang C; Liu Y; Yuan Z
    Int J Pharm; 2013 Jul; 451(1-2):1-11. PubMed ID: 23618965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced Reactive Oxygen Species Generation by Mitochondria Targeting of Anticancer Drug To Overcome Tumor Multidrug Resistance.
    Liu Y; Zhou Z; Lin X; Xiong X; Zhou R; Zhou M; Huang Y
    Biomacromolecules; 2019 Oct; 20(10):3755-3766. PubMed ID: 31465208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. pH-responsive complexes using prefunctionalized polymers for synchronous delivery of doxorubicin and siRNA to cancer cells.
    Dong DW; Xiang B; Gao W; Yang ZZ; Li JQ; Qi XR
    Biomaterials; 2013 Jul; 34(20):4849-59. PubMed ID: 23541420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual-Ligand-Functionalized Liposomes Based on Glycyrrhetinic Acid and cRGD for Hepatocellular Carcinoma Targeting and Therapy.
    Qiu M; Wang J; Bai J; Li X; Tian C; Liu Z; Zheng C; Clark AR; Cheng X; Liao X; Wu S; Lee RJ; Zhou X
    Mol Pharm; 2023 Apr; 20(4):1951-1963. PubMed ID: 36952242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.